Quantitative Investment Management LLC Purchases 54,849 Shares of Illumina, Inc. $ILMN

Key Points

• Quantitative Investment Management LLC significantly increased its stake in Illumina, Inc., purchasing an additional 54,849 shares, raising its holdings by 1,743.5% to a total of 57,995 shares valued at $4.6 million.
• A majority of Illumina's stock, approximately 89.42%, is owned by institutional investors, with other firms such as Vanguard and Brown Advisory also increasing their positions in the company during the first quarter.
• Illumina recently reported earnings of $1.19 EPS, surpassing analyst estimates, although revenue for the quarter was down 4.8% year-over-year at $1.06 billion.

Quantitative Investment Management LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1,743.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,995 shares of the life sciences company's stock after purchasing an additional 54,849 shares during the quarter. Quantitative Investment Management LLC's holdings in Illumina were worth $4,601,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Illumina by 3.5% during the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock worth $1,298,928,000 after purchasing an additional 558,243 shares in the last quarter. WCM Investment Management LLC boosted its position in shares of Illumina by 1.2% during the first quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock worth $334,321,000 after purchasing an additional 49,156 shares in the last quarter. Brown Advisory Inc. boosted its position in shares of Illumina by 52.1% during the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock worth $230,818,000 after purchasing an additional 996,589 shares in the last quarter. Northern Trust Corp boosted its position in shares of Illumina by 26.9% during the fourth quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock worth $220,882,000 after purchasing an additional 349,878 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Illumina by 2.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,292,407 shares of the life sciences company's stock worth $172,704,000 after purchasing an additional 32,270 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ILMN shares. Guggenheim reduced their price target on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Royal Bank Of Canada boosted their price objective on shares of Illumina from $118.00 to $126.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. Stephens set a $110.00 price objective on shares of Illumina and gave the company an "overweight" rating in a research report on Monday, August 4th. Wall Street Zen cut shares of Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Morgan Stanley boosted their price objective on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, August 4th. Seven equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $124.58.

Illumina Stock Up 2.5%

Illumina stock opened at $101.80 on Friday. The firm has a market capitalization of $15.65 billion, a PE ratio of 12.89, a P/E/G ratio of 2.29 and a beta of 1.37. The company's 50-day moving average is $98.18 and its 200-day moving average is $88.88. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina's quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.